14 Schoolhouse Road
Somerset, NJ 08873
T: +1 (888) 765-8846

Catalent is the global leader in enabling pharmaceutical, biotechnology, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients globally. With broad scale and deep expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Helping to accelerate over 1,000 partner programs, and launch over 150 new products every year, Catalent’s flexible manufacturing platforms, at over 50 global sites, supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including over 2,500 scientists.

Technology Highlights

In both the U.S. and Europe, Catalent has recently announced extensive investments to enhance and expand its full range of development and commercial drug substance and drug product capabilities across biotherapeutics, vaccines, and plasmids, as well as cell and gene therapies.

  • Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, as well as plasmid DNA. Its comprehensive cell therapy portfolio includes expertise across multiple cell types including CAR-T, autologous and allogeneic cell therapy development and manufacturing, and human induced pluripotent stem cells (iPSCs);
  • Advanced GPEx® cell line expression technology for biopharmaceutical development, bioanalytics and biomanufacturing;
  • Proprietary SMARTag® site-specific bioconjugation technology, affording precision design of next-generation biologic therapies;
  • OptiForm® Solution Suite for rapid, optimized dose form development and bioavailability enhancement technologies;
  • Catalent R P Scherer® softgel Rx and consumer health forms including oral and topical softgel technologies; gummies, soft-chews and lozenges;
  • Unique delivery technologies: including OptiShell® gelatin-free capsule technology; Zydis® orally disintegrating tablets; oral controlled release including OptiGel® DR; FlexDoseSM stick pack; and injectable forms;
  • Comprehensive inhaled dose form development capabilities for DPI, MDI and nasal spray delivery, including a commercial-scale spray dry dispersion facility in Boston, Massachusetts;
  • Integrated global clinical trial manufacturing and logistics network, with new supply facilities in San Diego and Japan opened in 2021.

Integrated Solutions

Catalent offers integrated development and product supply solutions that can be combined or tailored, to enable customers to progress drugs, biologics, and consumer health products from laboratory to market, faster. Post-launch, Catalent provides comprehensive, integrated product supply, from sourcing bulk API through to manufacturing and packaging, release testing, and distribution. These flexible, scalable, and creative solutions meet the unique needs of both large and emerging biopharma and consumer health companies.

More products. Better treatments. Reliably supplied.TM